Turkish Journal of Hematology (Sep 2024)

Management of Primary Immune Thrombocytopenia: Turkish Modified Delphi-Based Consensus Statement for Special Considerations

  • Elif Gülsüm Ümit,
  • Ahmet Muzaffer Demir,
  • Muhlis Cem Ar,
  • Mesut Ayer,
  • Meltem Aylı,
  • Volkan Karakuş,
  • Emin Kaya,
  • Fahir Özkalemkaş,
  • Nilgün Sayınalp,
  • Mehmet Sönmez,
  • Fahri Şahin,
  • Selami Koçak Toprak,
  • Tayfur Toptaş,
  • İrfan Yavaşoğlu,
  • Ümran Çalış

DOI
https://doi.org/10.4274/tjh.galenos.2024.2024.0101
Journal volume & issue
Vol. 41, no. 3
pp. 141 – 145

Abstract

Read online

Objective: Primary immune thrombocytopenia (ITP) is an acquired disorder of platelets with a complex and unclear mechanism of increased immune destruction or impaired production of platelets. While the management of ITP is evolving, there is still a need for guidance, particularly in certain circumstances such as pregnancy, emergencies, or patients requiring co-medications. We aimed to determine the tendencies of hematologists in Türkiye in the event of such special considerations. Materials and Methods: Applying a modified Delphi method, the Turkish National ITP Working Group, founded under the auspices of the Turkish Society of Hematology, developed a questionnaire consisting of statements regarding pregnancy, emergencies, and circumstances requiring co-treatment with antiaggregants or anticoagulants. A total of 107 hematologists working in university or state hospitals voted for their agreement or disagreement with the statements for two sequential rounds. Results: The participating hematologists reached an agreement on starting treatment for pregnant patients with platelets of less than 30x109/L and delivery either vaginally or by cesarean section being safe at platelet counts above 50x109/L. For emergencies and the rescue management of ITP, the panel agreed against the use of high-dose corticosteroids alone, preferring combinations with transfusions or intravenous immunoglobulin. For patients who require interventions, platelet counts of >50x109/L were regarded as safe for low-risk procedures as well as co-treatment with antiplatelets or anticoagulants. Conclusion: As the National ITP Study Group, we have observed the need to increase the practice guidance regarding patients with primary ITP requiring additional treatments including invasive interventions and co-treatments for coagulation. Decisions on the management of ITP during pregnancy should be individualized. There is a lack of consensus on the thresholds of platelet counts as well as co-morbidities and co-medications. This lack of consensus may be due to variations in practices.

Keywords